Birth defects monitoring

Klingberg, Marcus A.; Papier, Cheri M.; Hart, Jacob

doi:10.1002/ajim.4700040123

Cited by 12 publications

(5 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to 70% of BDs could either be prevented, or with proper care, cured or ameliorated [23,24]. As the largest developing country in the world, a hospital-based surveillance system for monitoring BDs was established in China in 1986 [25].…”

Section: Discussionmentioning

confidence: 99%

Analysis of Birth Defect Monitoring Data and Comparison of Prediction Models in Lanzhou, China

Jing¹,

Yang²,

Xie³

et al. 2020

A Epidemiol Public Health

View full text Add to dashboard Cite

Background:To analyze the distribution of birth defects in Lanzhou, China from 2012 to 2018, to forecast the prevalence in the future, and to provide evidence for prevention of birth defects. Materials and Methods:Monitoring datas for birth defects in Lanzhou from 2012 to 2018 were used to describe its epidemiological characteristics, such as the change of the prevalence and trend, urban-rural differences, the varieties and cis-position. Gray modeling, Curve estimation, Exponential smoothing, and ARIMA were used to predict the occurrence for the next year in the future. Results:The average prevalence rate of total perinatal infants' birth defects was 104.13 per 10000 perinatal infants in the past 7 years in Lanzhou, with an upward trend increasing by 7.74% on average each year. From 2012 to 2018, the average incidence of birth defects in urban and rural areas of Lanzhou was 105.61/10000 and 106.48/10000, respectively, and the overall trend was upward. The most common birth defects in Lanzhou from 2012 to 2018 were cleft lip ± cleft palate and Congenital heart disease. Exponential smoothing model can better fit the number of birth defects in Lanzhou. The predicted results of exponential smoothing model indicate that birth defects in Lanzhou in 2019 are lower than that in 2018.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Birth Defect Monitoring Data and Comparison of Prediction Models in Lanzhou, China

Jing¹,

Yang²,

Xie³

et al. 2020

A Epidemiol Public Health

View full text Add to dashboard Cite

show abstract

“…Elevated risks were observed for chromosomal defects as well as for cleft palatekleft lips. The combination of major malformations and the administration of insulin cannot be completely disregarded, but most authors view diabetes mellitus and not insulin as a risk factor [Cohen and Schenker, 1972;Miller et al, 1981;Mills, 1982;Molstedt-Pedersen, 1976;Soler et al, 19761. In the literature, mainly malformations of the musculoskeletal system, the nervous system, heart defects, and cleft palatekleft lips, as well as chromosomal aberrations, have been reported [Daw and Riley, 1984;Klingenberg et al, 1983;KuEera et al, 1965;Quaas et al, 1986;Schwaibold, 19851. Results obtained by our study therefore corroborate those reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

Serial examination of 20,248 newborn fetuses and infants: Correlations between drug exposure and major malformations

et al. 1996

View full text Add to dashboard Cite

Maternal medication during the first trimester of pregnancy has been discussed as a risk factor for development of birth defects. The correlation between maternal drug use and major malformations was investigated in a population-based case-control study in Mainz. Over a period of 5 years (1990-1994), 20,248 livebirths, stillbirths, and abortions underwent physical and sonographic examination, and anamnestic data were collected. A total of 1,472 births with congenital anomalies (cases) and 9,682 births without major and minor malformations (controls) were analyzed. We distinguished between 30 different drug categories, which were divided into medication taken continuously (before and during pregnancy; CM) and acute medication (drugs given within the first 3 months of gravidity; AM). Statistically highly-significant results [CM: Odds Ratios (OR) 1.2, Confidence Intervals (CI) 1.1-1.4, P = 0.008; AM: OR 1.2, CI 1.1-1.3, P = 0.008] were established for maternal drug use in correlation to birth defects. For the majority of combinations between drugs and specific malformations no teratogenic risks were found. However, statistically significant associations were recorded for antiallergics and heart anomalies (CM, AM) as well as musculoskeletal anomalies (AM); for bronchodilators and heart anomalies (CM, AM); for antiepileptics and anomalies of the internal urogenital system (CM), as well as cleft palate/cleft lips (AM); for thyroid hormones and anomalies of the nervous system (CM, AM), as well as anomalies of the external urogenital system (CM, AM); for insulin and anomalies of the musculoskeletal system (CM); for digitalis and anomalies of the musculoskeletal system (AM).

show abstract

“…Although the birth defects surveillance systems in the world provide invaluable data for descriptive and analytical epidemiologic studies, their effectiveness in detecting subtle epidemics has been criticized [Chen, 1979[Chen, , 1985Klingberg et al, 1983;Kä llén et al, 1984a;Khoury and Holtzman, 1987]. The classification of malformations used in monitoring has been discussed [Bod and Czeizel, 1981;Kä llén et al, 1984b;Holtzman and Khoury, 1986].…”

Section: Introductionmentioning

confidence: 99%

The return of thalidomide: Are birth defects surveillance systems ready?

et al. 1997

View full text Add to dashboard Cite

In the 1960s, thalidomide caused limb deficiencies in thousands of infants worldwide. The limb deficiencies were frequently of the intercalary type. As a result, numerous countries started birth defect surveillance programs. In 1967, the Centers for Disease Control (CDC) started the Metropolitan Atlanta Congenital Defects Program (MACDP), a population-based surveillance system, to provide early warning against new teratogens. Recent studies have shown that thalidomide may be beneficial for a range of conditions, including cancer and AIDS, and it may once again become widely available. Here, we examine the ability of MACDP to detect an increase in the birth prevalence of limb deficiency as an early warning of fetal exposure to thalidomide. We calculated base rates for all limb deficiencies, for bilateral nonsyndromic intercalary or preaxial deficiencies, and for all nonsyndromic intercalary limb deficiencies among Atlanta infants born from 1968 through 1993. We used relative risk estimates from previous studies and a range of pregnancy exposure rates for thalidomide. We tested the statistical power of MACDP to detect subtle changes in the birth prevalence of these defects using Poisson and cumulative sum (CUSUM) techniques. The base rates for all limb deficiencies, for bilateral intercalary or preaxial deficiencies, and for all intercalary limb deficiencies, were 0.53, 0.035, and 0.022/1,000, and the estimated relative risks were 175, 4,570, and 8,180, respectively. We varied the assumed rate of exposure to thalidomide from 1/10,000 to 5/100. With a 1/1,000 exposure rate, both Poisson and CUSUM techniques will detect a rate change in intercalary limb deficiency in about 6 months of monitoring, and a rate change in bilateral intercalary or preaxial deficiencies in about 12 months of monitoring. When monitoring all limb deficiencies, a pregnancy exposure rate of 3.5% or less would go unnoticed by the Poisson method and would take more than 50 years for the CUSUM method to signal an alarm with a 1/1,000 exposure rate. However, for rates of exposure less than 1/1,000, a progressively longer period of time or larger sample are needed to detect a rate change by both methods. Our findings highlight the importance of enlarging the monitored population and correct case classification in birth defects surveillance.

show abstract

Birth defects monitoring

Cited by 12 publications

References 76 publications

Analysis of Birth Defect Monitoring Data and Comparison of Prediction Models in Lanzhou, China

Analysis of Birth Defect Monitoring Data and Comparison of Prediction Models in Lanzhou, China

Serial examination of 20,248 newborn fetuses and infants: Correlations between drug exposure and major malformations

The return of thalidomide: Are birth defects surveillance systems ready?

Contact Info

Product

Resources

About